S&P 500   3,118.26 (-0.12%)
DOW   27,926.20 (-0.39%)
QQQ   203.05 (-0.01%)
CGC   15.04 (+5.77%)
BABA   184.34 (-0.15%)
T   38.34 (-3.28%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
BAC   32.84 (-0.36%)
DIS   147.38 (-0.18%)
S&P 500   3,118.26 (-0.12%)
DOW   27,926.20 (-0.39%)
QQQ   203.05 (-0.01%)
CGC   15.04 (+5.77%)
BABA   184.34 (-0.15%)
T   38.34 (-3.28%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
BAC   32.84 (-0.36%)
DIS   147.38 (-0.18%)
S&P 500   3,118.26 (-0.12%)
DOW   27,926.20 (-0.39%)
QQQ   203.05 (-0.01%)
CGC   15.04 (+5.77%)
BABA   184.34 (-0.15%)
T   38.34 (-3.28%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
BAC   32.84 (-0.36%)
DIS   147.38 (-0.18%)
S&P 500   3,118.26 (-0.12%)
DOW   27,926.20 (-0.39%)
QQQ   203.05 (-0.01%)
CGC   15.04 (+5.77%)
BABA   184.34 (-0.15%)
T   38.34 (-3.28%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
BAC   32.84 (-0.36%)
DIS   147.38 (-0.18%)
Log in

Opko Health Stock Price, Forecast & Analysis (NASDAQ:OPK)

$1.47
-0.01 (-0.68 %)
(As of 11/19/2019 11:20 AM ET)
Today's Range
$1.45
Now: $1.47
$1.50
50-Day Range
$1.42
MA: $1.78
$2.15
52-Week Range
$1.33
Now: $1.47
$3.93
Volume196,073 shs
Average Volume8.65 million shs
Market Capitalization$978.43 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$990.30 million
Book Value$3.06 per share

Profitability

Net Income$-153,040,000.00

Miscellaneous

Employees5,690
Market Cap$978.43 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.


Opko Health (NASDAQ:OPK) Frequently Asked Questions

What is Opko Health's stock symbol?

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

How were Opko Health's earnings last quarter?

Opko Health Inc. (NASDAQ:OPK) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The biotechnology company earned $228.80 million during the quarter, compared to analyst estimates of $225.40 million. Opko Health had a negative return on equity of 14.42% and a negative net margin of 30.98%. The business's revenue for the quarter was down 8.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) EPS. View Opko Health's Earnings History.

When is Opko Health's next earnings date?

Opko Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Opko Health.

What price target have analysts set for OPK?

1 brokerages have issued 1 year price targets for Opko Health's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Opko Health's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 172.1% from the stock's current price. View Analyst Price Targets for Opko Health.

What is the consensus analysts' recommendation for Opko Health?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.

What are Wall Street analysts saying about Opko Health stock?

Here are some recent quotes from research analysts about Opko Health stock:
  • 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time." (10/18/2019)
  • 2. Barrington Research analysts commented, "We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline." (9/12/2019)

Has Opko Health been receiving favorable news coverage?

Headlines about OPK stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Opko Health earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Opko Health.

Are investors shorting Opko Health?

Opko Health saw a decrease in short interest in October. As of October 31st, there was short interest totalling 74,550,000 shares, a decrease of 12.1% from the September 30th total of 84,770,000 shares. Based on an average daily trading volume, of 4,830,000 shares, the days-to-cover ratio is currently 15.4 days. Approximately 19.5% of the company's stock are short sold. View Opko Health's Current Options Chain.

Who are some of Opko Health's key competitors?

What other stocks do shareholders of Opko Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), bluebird bio (BLUE), Micron Technology (MU), Gray Television (GTN), Allergan (AGN), Gilead Sciences (GILD), Bausch Health Companies (BHC), AT&T (T), NVIDIA (NVDA) and Novavax (NVAX).

Who are Opko Health's key executives?

Opko Health's management team includes the folowing people:
  • Dr. Phillip Frost, Chairman & CEO (Age 83)
  • Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
  • Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
  • Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)

Who are Opko Health's major shareholders?

Opko Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include RK Asset Management LLC (0.20%), California Public Employees Retirement System (0.11%), Rhumbline Advisers (0.09%), Mackay Shields LLC (0.07%), Commonwealth Equity Services LLC (0.07%) and Gabelli Funds LLC (0.03%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.

Which institutional investors are selling Opko Health stock?

OPK stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC and SG Americas Securities LLC. View Insider Buying and Selling for Opko Health.

Which institutional investors are buying Opko Health stock?

OPK stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Gamco Investors INC. ET AL, Rhumbline Advisers, RK Asset Management LLC, Mackay Shields LLC, Alpha Cubed Investments LLC and Commonwealth Equity Services LLC. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.

How do I buy shares of Opko Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Opko Health's stock price today?

One share of OPK stock can currently be purchased for approximately $1.47.

How big of a company is Opko Health?

Opko Health has a market capitalization of $978.43 million and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.View Additional Information About Opko Health.

What is Opko Health's official website?

The official website for Opko Health is http://www.opko.com/.

How can I contact Opko Health?

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]


MarketBeat Community Rating for Opko Health (NASDAQ OPK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  419 (Vote Outperform)
Underperform Votes:  399 (Vote Underperform)
Total Votes:  818
MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel